Literature DB >> 22863616

When NK cells overcome their lack of education.

Baptiste N Jaeger1, Eric Vivier.   

Abstract

Cells of the immune system have evolved various molecular mechanisms to sense their environment and react to alterations of self. NK cells are lymphocytes with effector and regulatory functions, which are remarkably adaptable to changes in self. In a study published in this issue of the JCI, Tarek and colleagues report the clinical benefits of manipulating NK cell adaptation to self in an innovative mAb-based therapy against neuroblastoma (NB). This novel therapeutic strategy should stimulate further research on NK cell therapies.

Entities:  

Year:  2012        PMID: 22863616      PMCID: PMC3428094          DOI: 10.1172/JCI63524

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

Review 1.  MHC class I molecules and KIRs in human history, health and survival.

Authors:  Peter Parham
Journal:  Nat Rev Immunol       Date:  2005-03       Impact factor: 53.106

2.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

Review 3.  Self-tolerance of natural killer cells.

Authors:  David H Raulet; Russell E Vance
Journal:  Nat Rev Immunol       Date:  2006-07       Impact factor: 53.106

Review 4.  Beyond licensing and disarming: a quantitative view on NK-cell education.

Authors:  Petter Brodin; Petter Höglund
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

5.  Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice.

Authors:  M Bix; N S Liao; M Zijlstra; J Loring; R Jaenisch; D Raulet
Journal:  Nature       Date:  1991-01-24       Impact factor: 49.962

6.  Human NK cell education by inhibitory receptors for MHC class I.

Authors:  Nicolas Anfossi; Pascale André; Sophie Guia; Christine S Falk; Sophie Roetynck; C Andrew Stewart; Violette Breso; Coralie Frassati; Denis Reviron; Derek Middleton; François Romagné; Sophie Ugolini; Eric Vivier
Journal:  Immunity       Date:  2006-08-10       Impact factor: 31.745

7.  'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection.

Authors:  Mark T Orr; William J Murphy; Lewis L Lanier
Journal:  Nat Immunol       Date:  2010-02-28       Impact factor: 25.606

8.  MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment.

Authors:  Julie M Elliott; Joseph A Wahle; Wayne M Yokoyama
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

Review 9.  How do natural killer cells find self to achieve tolerance?

Authors:  Wayne M Yokoyama; Sungjin Kim
Journal:  Immunity       Date:  2006-03       Impact factor: 31.745

10.  Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

Authors:  Francois Romagné; Pascale André; Pieter Spee; Stefan Zahn; Nicolas Anfossi; Laurent Gauthier; Marusca Capanni; Loredana Ruggeri; Don M Benson; Bradley W Blaser; Mariella Della Chiesa; Alessandro Moretta; Eric Vivier; Michael A Caligiuri; Andrea Velardi; Nicolai Wagtmann
Journal:  Blood       Date:  2009-06-24       Impact factor: 22.113

View more
  5 in total

Review 1.  Natural killer cell receptors: alterations and therapeutic targeting in malignancies.

Authors:  Gordana Konjević; Ana Vuletić; Katarina Mirjačić Martinović
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

2.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

3.  Lirilumab and Avelumab Enhance Anti-HPV+ Cervical Cancer Activity of Natural Killer Cells via Vav1-Dependent NF-κB Disinhibition.

Authors:  Hongli Liu; Sihui Zhou; Jing Liu; Fuliang Chen; Yuan Zhang; Mengjun Liu; Shengping Min; Hongtao Wang; Xiaojing Wang; Nan Wu
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

Review 4.  Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches.

Authors:  Sebastian Carotta
Journal:  Front Immunol       Date:  2016-04-21       Impact factor: 7.561

Review 5.  NK cell education via nonclassical MHC and non-MHC ligands.

Authors:  Yuke He; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.